<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">30739869</PMID>
      <DateCompleted>
        <Year>2019</Year>
        <Month>05</Month>
        <Day>06</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2020</Year>
        <Month>03</Month>
        <Day>09</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">2352-345X</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>7</Volume>
            <Issue>2</Issue>
            <PubDate>
              <Year>2019</Year>
            </PubDate>
          </JournalIssue>
          <Title>Cellular and molecular gastroenterology and hepatology</Title>
          <ISOAbbreviation>Cell Mol Gastroenterol Hepatol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Resolving the Paradox of Hepatic Insulin Resistance.</ArticleTitle>
        <Pagination>
          <StartPage>447</StartPage>
          <EndPage>456</EndPage>
          <MedlinePgn>447-456</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jcmgh.2018.10.016</ELocationID>
        <ELocationID EIdType="pii" ValidYN="Y">S2352-345X(18)30162-0</ELocationID>
        <Abstract>
          <AbstractText>Insulin resistance is associated with numerous metabolic disorders, such as obesity and type II diabetes, that currently plague our society. Although insulin normally promotes anabolic metabolism in the liver by increasing glucose consumption and lipid synthesis, insulin-resistant individuals fail to inhibit hepatic glucose production and paradoxically have increased liver lipid synthesis, leading to hyperglycemia and hypertriglyceridemia. Here, we detail the intrahepatic and extrahepatic pathways mediating insulin's control of glucose and lipid metabolism. We propose that the interplay between both of these pathways controls insulin signaling and that mis-regulation between the 2 results in the paradoxic effects seen in the insulin-resistant liver instead of the commonly proposed deficiencies in particular branches of only the direct hepatic pathway.</AbstractText>
          <CopyrightInformation>Copyright © 2019 The Authors. Published by Elsevier Inc. All rights reserved.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Santoleri</LastName>
            <ForeName>Dominic</ForeName>
            <Initials>D</Initials>
            <AffiliationInfo>
              <Affiliation>Biochemistry and Molecular Biophysics Graduate Group, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Titchenell</LastName>
            <ForeName>Paul M</ForeName>
            <Initials>PM</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Physiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania; Institute for Diabetes, Obesity, and Metabolism, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania. Electronic address: ptitc@pennmedicine.upenn.edu.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>K01 DK111715</GrantID>
            <Acronym>DK</Acronym>
            <Agency>NIDDK NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>P30 DK019525</GrantID>
            <Acronym>DK</Acronym>
            <Agency>NIDDK NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2018</Year>
          <Month>11</Month>
          <Day>03</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Cell Mol Gastroenterol Hepatol</MedlineTA>
        <NlmUniqueID>101648302</NlmUniqueID>
        <ISSNLinking>2352-345X</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D007328">Insulin</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007328" MajorTopicYN="N">Insulin</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007333" MajorTopicYN="Y">Insulin Resistance</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D050356" MajorTopicYN="N">Lipid Metabolism</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008099" MajorTopicYN="N">Liver</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008954" MajorTopicYN="N">Models, Biological</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="Y">De Novo Lipogenesis</Keyword>
        <Keyword MajorTopicYN="Y">Hepatic Glucose Production</Keyword>
        <Keyword MajorTopicYN="Y">Hepatic Insulin Resistance</Keyword>
        <Keyword MajorTopicYN="Y">Insulin Signaling</Keyword>
        <Keyword MajorTopicYN="Y">Metabolism</Keyword>
        <Keyword MajorTopicYN="Y">PI3K/Akt Signaling Pathway</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2018</Year>
          <Month>9</Month>
          <Day>17</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2018</Year>
          <Month>10</Month>
          <Day>30</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2018</Year>
          <Month>10</Month>
          <Day>30</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2019</Year>
          <Month>2</Month>
          <Day>12</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2019</Year>
          <Month>5</Month>
          <Day>7</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2019</Year>
          <Month>2</Month>
          <Day>12</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">30739869</ArticleId>
        <ArticleId IdType="pmc">PMC6369222</ArticleId>
        <ArticleId IdType="doi">10.1016/j.jcmgh.2018.10.016</ArticleId>
        <ArticleId IdType="pii">S2352-345X(18)30162-0</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Zimmet P., Alberti K.G.M.M., Shaw J. Global and societal implications of the diabetes epidemic. Nature. 2001;414:782–787.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11742409</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ramnanan C.J., Edgerton D.S., Kraft G., Cherrington A.D. Physiologic action of glucagon on liver glucose metabolism. Diabetes Obes Metab. 2011;13(Suppl 1):118–125.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5371022</ArticleId>
            <ArticleId IdType="pubmed">21824265</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lin H.V., Accili D. Hormonal regulation of hepatic glucose production in health and disease. Cell Metab. 2011;14:9–19.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3131084</ArticleId>
            <ArticleId IdType="pubmed">21723500</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brown M.S., Goldstein J.L. Selective versus total insulin resistance: a pathogenic paradox. Cell Metab. 2008;7:95–96.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18249166</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>James O.F.W., Day C.P. Non-alcoholic steatohepatitis (NASH): a disease of emerging identity and importance. J Hepatol. 1998;29:495–501.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9765002</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sanyal A.J., Campbell-Sargent C., Mirshahi F., Rizzo W.B., Contos M.J., Sterling R.K., Luketic V.A., Shiffman M.L., Clore J.N. Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. Gastroenterology. 2001;120:1183–1192.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11266382</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gastaldelli A., Cusi K., Pettiti M., Hardies J., Miyazaki Y., Berria R., Buzzigoli E., Sironi A.M., Cersosimo E., Ferrannini E., DeFronzo R.A. Relationship between hepatic/visceral fat and hepatic insulin resistance in nondiabetic and type 2 diabetic subjects. Gastroenterology. 2007;133:496–506.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17681171</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lambert J.E., Ramos-Roman M.A., Browning J.D., Parks E.J. Increased de novo lipogenesis is a distinct characteristic of individuals with nonalcoholic fatty liver disease. Gastroenterology. 2014;146:726–735.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6276362</ArticleId>
            <ArticleId IdType="pubmed">24316260</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Roden M., Stingl H., Chandramouli V., Schumann W.C., Hofer A., Landau B.R., Nowotny P., Waldhäusl W., Shulman G.I. Effects of free fatty acid elevation on and gluconeogenesis in humans. Endocrinol Metab. 2000;49:701–707.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10905476</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sunny N.E., Parks E.J., Browning J.D., Burgess S.C. Excessive hepatic mitochondrial TCA cycle and gluconeogenesis in humans with nonalcoholic fatty liver disease. Cell Metab. 2011;14:804–810.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3658280</ArticleId>
            <ArticleId IdType="pubmed">22152305</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Biddinger S.B., Hernandez-Ono A., Rask-Madsen C., Haas J.T., Alemán J.O., Suzuki R., Scapa E.F., Agarwal C., Carey M.C., Stephanopoulos G., Cohen D.E., King G.L., Ginsberg H.N.N., Kahn C.R. Hepatic insulin resistance is sufficient to produce dyslipidemia and susceptibility to atherosclerosis. Cell Metab. 2008;7:125–134.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4251554</ArticleId>
            <ArticleId IdType="pubmed">18249172</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Haas J.T., Miao J., Chanda D., Wang Y., Zhao E., Haas M.E., Hirschey M., Vaitheesvaran B., Farese R.V., Jr., Kurland I.J., Graham M., Crooke R., Foufelle F., Biddinger S.B. Hepatic insulin signaling is required for obesity-dependent expression of SREBP-1c mRNA but not for feeding-dependent expression. Cell Metab. 2012;15:873–884.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3383842</ArticleId>
            <ArticleId IdType="pubmed">22682225</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Semple R.K., Sleigh A., Murgatroyd P.R., Adams C.A., Bluck L., Jackson S., Vottero A., Kanabar D., Charlton-Menys V., Durrington P., Soos M.A., Carpenter T.A., Lomas D.J., Cochran E.K., Gorden P., O'Rahilly S., Savage D.B. Postreceptor insulin resistance contributes to human dyslipidemia and hepatic steatosis. J Clin Invest. 2009;119:315–322.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2631303</ArticleId>
            <ArticleId IdType="pubmed">19164855</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Michael M.D., Kulkarni R.N., Postic C., Previs S.F., Shulman G.I., Magnuson M.A., Kahn C.R. Loss of insulin signaling in hepatocytes leads to severe insulin resistance and progressive hepatic dysfunction. Mol Cell. 2000;6:87–97.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10949030</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Softic S., Boucher J., Solheim M.H., Fujisaka S., Haering M.F., Homan E.P., Winnay J., Perez-Atayde A.R., Kahn C.R. Lipodystrophy due to adipose tissue-specific insulin receptor knockout results in progressive NAFLD. Diabetes. 2016;65:2187–2200.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4955986</ArticleId>
            <ArticleId IdType="pubmed">27207510</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Titchenell P.M., Chu Q., Monks B.R., Birnbaum M.J. Hepatic insulin signaling is dispensible for suppression of glucose output by insulin in vivo. Nat Commun. 2015;6:7078.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4429930</ArticleId>
            <ArticleId IdType="pubmed">25963408</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Taniguchi C.M., Emanuelli B., Kahn C.R. Critical nodes in signalling pathways: insights into insulin action. Nat Rev Mol Cell Biol. 2006;7:85–96.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16493415</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gual P., Le Marchand-Brustel Y., Tanti J.F. Positive and negative regulation of insulin signaling through IRS-1 phosphorylation. Biochimie. 2005;87:99–109.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15733744</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dong X.C., Copps K.D., Guo S., Li Y., Kollipara R., DePinho R.A., White M.F. Inactivation of hepatic Foxo1 by insulin signaling is required for adaptive nutrient homeostasis and endocrine growth regulation. Cell Metab. 2008;8:65–76.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2929667</ArticleId>
            <ArticleId IdType="pubmed">18590693</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kubota N., Kubota T., Kajiwara E., Iwamura T., Kumagai H., Watanabe T., Inoue M., Takamoto I., Sasako T., Kumagai K., Kohjima M., Nakamuta M., Moroi M., Sugi K., Noda T., Terauchi Y., Ueki K., Kadowaki T. Differential hepatic distribution of insulin receptor substrates causes selective insulin resistance in diabetes and obesity. Nat Commun. 2016;7:12977.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5059684</ArticleId>
            <ArticleId IdType="pubmed">27708333</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Miyake K., Ogawa W., Matsumoto M., Nakamura T., Sakaue H., Kasuga M. Hyperinsulinemia, glucose intolerance, and dyslipidemia induced by acute inhibition of phosphoinositide 3-kinase signaling in the liver. J Clin Invest. 2002;110:1483–1491.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC151813</ArticleId>
            <ArticleId IdType="pubmed">12438446</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Taniguchi C.M., Kondo T., Sajan M., Luo J., Bronson R., Asano T., Farese R., Cantley L.C., Kahn C.R. Divergent regulation of hepatic glucose and lipid metabolism by phosphoinositide 3-kinase via Akt and PKCλ/ζ. Cell Metab. 2006;3:343–353.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16679292</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chattopadhyay M., Selinger E.S., Ballou L.M., Lin R.Z. Ablation of PI3K p110-α prevents high-fat diet-induced liver steatosis. Diabetes. 2011;60:1483–1492.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3292322</ArticleId>
            <ArticleId IdType="pubmed">21464441</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mora A., Lipina C., Tronche F., Sutherland C., Alessi D.R. Deficiency of PDK1 in liver results in glucose intolerance, impairment of insulin-regulated gene expression and liver failure. Biochem J. 2005;385:639–648.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1134738</ArticleId>
            <ArticleId IdType="pubmed">15554902</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Horie Y., Suzuki A., Kataoka E., Sasaki T., Hamada K., Sasaki J., Mizuno K., Hasegawa G., Kishimoto H., Iizuka M., Naito M., Enomoto K., Watanabe S., Mak T.W., Nakano T. Hepatocyte-specific Pten deficiency results in steatohepatitis and hepatocellular carcinomas. J Clin Invest. 2004;113:1774–1783.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC420505</ArticleId>
            <ArticleId IdType="pubmed">15199412</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>He L., Hou X., Kanel G., Zeng N., Galicia V., Wang Y., Yang J., Wu H., Birnbaum M.J., Stiles B.L. The critical role of AKT2 in hepatic steatosis induced by PTEN loss. Am J Pathol. 2010;176:2302–2308.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2861095</ArticleId>
            <ArticleId IdType="pubmed">20348245</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sarbassov D.D., Guertin D.A., Ali S.M. Phosphorylation and Regulation of Akt/PKB by the rictor-mTOR complex. Science. 2005;307:1098–1102.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15718470</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Garofalo R.S., Orena S.J., Rafidi K., Torchia A.J., Stock J.L., Hildebrandt A.L., Coskran T., Black S.C., Brees D.J., Wicks J.R., McNeish J.D., Coleman K.G. Severe diabetes, age-dependent loss of adipose tissue, and mild growth deficiency in mice lacking Akt2/PKBβ. J Clin Invest. 2003;112:197–208.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC164287</ArticleId>
            <ArticleId IdType="pubmed">12843127</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cho H., Mu J., Kim J.K., Thorvaldsen J.L., Chu Q., Crenshaw E.B., III, Kaestner K.H., Bartolomei M.S., Shulman G.I., Birnbaum M.J. Insulin resistance and a diabetes mellitus-like syndrome in mice lacking the protein kinase Akt2 (PKBbeta) Science. 2001;292:1728–1731.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11387480</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Leavens K.F., Easton R.M., Shulman G.I., Previs S.F., Birnbaum M.J. Akt2 is required for hepatic lipid accumulation in models of insulin resistance. Cell Metab. 2009;10:405–418.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2796129</ArticleId>
            <ArticleId IdType="pubmed">19883618</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lu M., Wan M., Leavens K.F., Chu Q., Monks B.R., Ahima R.S., Ueki K., Kahn C.R., Birnbaum M.J. Insulin regulates liver metabolism in vivo in the absence of hepatic Akt and Foxo1. Nat Med. 2012;18:388–395.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3296881</ArticleId>
            <ArticleId IdType="pubmed">22344295</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Titchenell P.M., Quinn W.J., Lu M., Chu Q., Lu W., Li C., Chen H., Monks B.R., Chen J., Rabinowitz J.D., Birnbaum M.J. Direct hepatocyte insulin signaling is required for lipogenesis but is dispensable for the suppression of glucose production. Cell Metab. 2016;23:1154–1166.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4909537</ArticleId>
            <ArticleId IdType="pubmed">27238637</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Menon S., Dibble C.C., Talbott G., Hoxhaj G., Valvezan A.J., Takahashi H., Cantley L.C., Manning B.D. Spatial control of the TSC complex integrates insulin and nutrient regulation of mtorc1 at the lysosome. Cell. 2014;156:1771–1785.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4030681</ArticleId>
            <ArticleId IdType="pubmed">24529379</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Howell J.J., Ricoult S.J.H., Ben-Sahra I., Manning B.D. A growing role for mTOR in promoting anabolic metabolism. Biochem Soc Trans. 2013;41:906–912.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23863154</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schwarz J.M., Linfoot P., Dare D., Aghajanian K. Hepatic de novo lipogenesis in normoinsulinemic and hyperinsulinemic subjects consuming high-fat, low-carbohydrate and low-fat, high-carbohydrate isoenergetic diets. Am J Clin Nutr. 2003;77:43–50.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12499321</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Savage D.B., Petersen K.F., Shulman G.I. Disordered lipid metabolism and the pathogenesis of insulin resistance. 2007;87:507–520.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2995548</ArticleId>
            <ArticleId IdType="pubmed">17429039</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wan M., Leavens K.F., Saleh D., Easton R.M., Guertin D.A., Peterson T.R., Kaestner K.H., Sabatini D.M., Birnbaum M.J. Postprandial hepatic lipid metabolism requires signaling through Akt2 independent of the transcription factors FoxA2, FoxO1, and SREBP1c. Cell Metab. 2011;14:516–527.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3190164</ArticleId>
            <ArticleId IdType="pubmed">21982711</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yecies J.L., Zhang H.H., Menon S., Liu S., Yecies D., Lipovsky A.I., Gorgun C., Kwiatkowski D.J., Hotamisligil G.S., Lee C.H., Manning B.D. Akt stimulates hepatic SREBP1c and lipogenesis through parallel mTORC1-dependent and independent pathways. Cell Metab. 2011;14:21–32.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3652544</ArticleId>
            <ArticleId IdType="pubmed">21723501</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Horton J.D., Goldstein J.L., Brown M.S. SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver. J Clin Invest. 2002;109:1125–1131.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC150968</ArticleId>
            <ArticleId IdType="pubmed">11994399</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Düvel K., Yecies J.L., Menon S., Raman P., Lipovsky A.I., Souza A.L., Triantafellow E., Ma Q., Gorski R., Cleaver S., Vander Heiden M.G., MacKeigan J.P., Finan P.M., Clish C.B., Murphy L.O., Manning B.D. Activation of a metabolic gene regulatory network downstream of mTOR complex 1. Mol Cell. 2010;39:171–183.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2946786</ArticleId>
            <ArticleId IdType="pubmed">20670887</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Owen J.L., Zhang Y., Bae S.-H., Farooqi M.S., Liang G., Hammer R.E., Goldstein J.L., Brown M.S. Insulin stimulation of SREBP-1c processing in transgenic rat hepatocytes requires p70 S6-kinase. Proc Natl Acad Sci U S A. 2012;109:16184–16189.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3479583</ArticleId>
            <ArticleId IdType="pubmed">22927400</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shimomura I., Bashmakov Y., Horton J.D. Increased levels of nuclear SREBP-1c associated with fatty livers in two mouse models of diabetes mellitus increased levels of nuclear SREBP-1c associated with fatty livers in two mouse models of diabetes mellitus. J Biol Chem. 1999;274:30028–30032.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10514488</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Moon Y.A., Liang G., Xie X., Frank-Kamenetsky M., Fitzgerald K., Koteliansky V., Brown M.S., Goldstein J.L., Horton J.D. The Scap/SREBP pathway is essential for developing diabetic fatty liver and carbohydrate-induced hypertriglyceridemia in animals. Cell Metab. 2012;15:240–246.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3662050</ArticleId>
            <ArticleId IdType="pubmed">22326225</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brown M.S., Goldstein J.L. The SREBP pathway: regulation of cholesterol metabolism by proteolysis of a membrane-bound transcription factor. Cell. 1997;89:331–340.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9150132</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Matsuda M., Korn B.S., Hammer R.E., Moon Y.A., Komuro R., Horton J.D., Goldstein J.L., Brown M.S., Shimomura I. SREBP cleavage-activating protein (SCAP) is required for increased lipid synthesis in liver induced by cholesterol deprivation and insulin elevation. Genes Dev. 2001;15:1206–1216.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC313801</ArticleId>
            <ArticleId IdType="pubmed">11358865</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dentin R., Tomas-Cobos L., Foufelle F., Leopold J., Girard J., Postic C., Ferré P. Glucose 6-phosphate, rather than xylulose 5-phosphate, is required for the activation of ChREBP in response to glucose in the liver. J Hepatol. 2012;56:199–209.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21835137</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Iizuka K., Bruick R.K., Liang G., Horton J.D., Uyeda K. Deficiency of carbohydrate response element-binding protein (ChREBP) reduces lipogenesis as well as glycolysis. Proc Natl Acad Sci U S A. 2004;101:7281–7286.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC409910</ArticleId>
            <ArticleId IdType="pubmed">15118080</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Iizuka K., Miller B., Uyeda K. Deficiency of carbohydrate-activated transcription factor ChREBP prevents obesity and improves plasma glucose control in leptin-deficient (ob/ob) mice. Am J Physiol Endocrinol Metab. 2006;291:E358–E364.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16705063</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Benhamed F., Denechaud P.D., Lemoine M., Robichon C., Moldes M., Bertrand-Michel J., Ratziu V., Serfaty L., Housset C., Capeau J., Girard J., Guillou H., Postic C. The lipogenic transcription factor ChREBP dissociates hepatic steatosis from insulin resistance in mice and humans. J Clin Invest. 2012;122:2176–2194.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3366390</ArticleId>
            <ArticleId IdType="pubmed">22546860</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hurtado Del Pozo C., Vesperinas-García G., Rubio M.Á., Corripio-Sánchez R., Torres-García A.J., Obregon M.J., Calvo R.M. ChREBP expression in the liver, adipose tissue and differentiated preadipocytes in human obesity. Biochim Biophys Acta. 2011;1811:1194–1200.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21840420</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jois T., Chen W., Howard V., Harvey R., Youngs K., Thalmann C., Saha P., Chan L., Cowley M.A., Sleeman M.W. Deletion of hepatic carbohydrate response element binding protein (ChREBP) impairs glucose homeostasis and hepatic insulin sensitivity in mice. Mol Metab. 2017;6:1381–1394.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5681238</ArticleId>
            <ArticleId IdType="pubmed">29107286</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Linden A.G., Li S., Choi H.Y., Fang F., Fukasawa M., Uyeda K., Hammer R.E., Horton J.D., Engelking L.J., Liang G. Interplay between ChREBP and SREBP-1c coordinates postprandial glycolysis and lipogenesis in livers of mice. J Lipid Res. 2018;59:475–487.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5832931</ArticleId>
            <ArticleId IdType="pubmed">29335275</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Poulsen M.K., Nellemann B., Stødkilde-Jørgensen H., Pedersen S.B., Grønbæk H., Nielsen S. Impaired insulin suppression of VLDL-triglyceride kinetics in nonalcoholic fatty liver disease. J Clin Endocrinol Metab. 2016;101:1637–1646.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26829441</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lewis G.F., Uffelman K.D., Szeto L.W., Steiner G. Effects of acute hyperinsulinemia on VLDL triglyceride and VLDL ApoB production in normal weight and obese individuals. Diabetes. 1993;42:833–842.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8495807</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ginsberg H.N., Zhang Y.-L., Hernandez-ono A. Metabolic syndrome : focus on dyslipidemia. Obesity. 2006;14:41–49.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16642962</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Steiner G., Haynes F.J., Yoshino G., Vranic M. Hyperinsulinemia and in vivo very-low-density lipoprotein-triglyceride kinetics. Am J Physiol Endocrinol Metab. 1984;246:187–192.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">6364843</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Han S., Liang C.P., Westerterp M., Senokuchi T., Welch C.L., Wang O., Matsumoto M., Accili D., Tall A.R. Hepatic insulin signaling regulates VLDL secretion and atherogenesis in mice. J Clin Invest. 2009;119:1029–1041.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2662550</ArticleId>
            <ArticleId IdType="pubmed">19273907</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Quinn W.J., Wan M., Shewale S.V., Gelfer R., Rader D.J., Birnbaum M.J., Titchenell P.M. MTORC1 stimulates phosphatidylcholine synthesis to promote triglyceride secretion. J Clin Invest. 2017;127:4207–4215.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5663357</ArticleId>
            <ArticleId IdType="pubmed">29035283</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gross D.N., Wan M., Birnbaum M.J. The role of FOXO in the regulation of metabolism. Curr Diab Rep. 2008;9:208–214.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19490822</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang W., Patil S., Chauhan B., Guo C., Powell D.R., Le J., Klotsas A., Matika R., Xiao X., Franks R., Heidenreich K.A., Sajan M.P., Farese R.V., Stolz D.B., Tso P., Koo S.H., Montminy M., Unterman T.G. FoxO1 regulates multiple metabolic pathways in the liver effects on gluconeogenic, glycolytic, and lipogenic gene expression. J Biol Chem. 2006;281:10105–10117.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16492665</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang W., Bu S.Y., Mashek M.T., O-Sullivan I., Sibai Z., Khan S.A., Ikayeva O., Newgard C.B., Mashek D.G., Unterman T.G. Integrated regulation of hepatic lipid and glucose metabolism by ATGL and FoxO proteins. Cell Rep. 2016;15:349–359.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5346032</ArticleId>
            <ArticleId IdType="pubmed">27050511</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Haeusler R.A., Hartil K., Vaitheesvaran B., Arrieta-Cruz I., Knight C.M., Cook J.R., Kammoun H.L., Febbraio M.A., Gutierrez-Juarez R., Kurland I.J., Accili D. Integrated control of hepatic lipogenesis versus glucose production requires FoxO transcription factors. Nat Commun. 2014;5:5190.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4197140</ArticleId>
            <ArticleId IdType="pubmed">25307742</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Deng X., Zhang W., O-Sullivan I.S., Williams J.B., Dong Q., Park E.A., Raghow R., Unterman T.G., Elam M.B. FoxO1 inhibits sterol regulatory element-binding protein-1c (SREBP-1c) gene expression via transcription factors Sp1 and SREBP-1c. J Biol Chem. 2012;287:20132–20143.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3370196</ArticleId>
            <ArticleId IdType="pubmed">22511764</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hirota K., Sakamaki J.I., Ishida J., Shimamoto Y., Nishihara S., Kodama N., Ohta K., Yamamoto M., Tanimoto K., Fukamizu A. A combination of HNF-4 and Foxo1 is required for reciprocal transcriptional regulation of glucokinase and glucose-6-phosphatase genes in response to fasting and feeding. J Biol Chem. 2008;283:32432–32441.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18805788</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Langlet F., Haeusler R.A., Lindén D., Ericson E., Norris T., Johansson A., Cook J.R., Aizawa K., Wang L., Buettner C., Accili D. Selective inhibition of FOXO1 activator/repressor balance modulates hepatic glucose handling. Cell. 2017;171:824–835.e18.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5687849</ArticleId>
            <ArticleId IdType="pubmed">29056338</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rizza R.A. Pathogenesis of fasting and postprandial hyperglycemia in type 2 diabetes: implications for therapy. Diabetes. 2010;59:2697–2707.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2963523</ArticleId>
            <ArticleId IdType="pubmed">20705776</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cross D.A., Alessi D.R., Cohen P., Andjelkovich M., Hemmings B.A. Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature. 1995;378:785–789.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8524413</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wan M., Leavens K.F., Hunter R.W., Shlomit Koren, Von Wilamowitz-Moellendorff A., Lu M., Satapati S., Chu Q., Sakamoto K., Burgess S.C., Birnbaum M.J. A noncanonical, GSK3-independent pathway controls postprandial hepatic glycogen deposition. Cell Metab. 2013;18:99–105.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3725134</ArticleId>
            <ArticleId IdType="pubmed">23823480</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Von Wilamowitz-Moellendorff A., Hunter R.W., García-Rocha M., Kang L., López-Soldado I., Lantier L., Patel K., Peggie M.W., Martínez-Pons C., Voss M., Calbó J., Cohen P.T.W., Wasserman D.H., Guinovart J.J., Sakamoto K. Glucose-6-phosphate-mediated activation of liver glycogen synthase plays a key role in hepatic glycogen synthesis. Diabetes. 2013;62:4070–4082.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3837029</ArticleId>
            <ArticleId IdType="pubmed">23990365</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Moore M.C., Coate K.C., Winnick J.J., An Z., Cherrington A.D. Regulation of hepatic glucose uptake and storage in vivo. Adv Nutr. 2012;3:286–294.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3649460</ArticleId>
            <ArticleId IdType="pubmed">22585902</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cherrington A.D., Edgerton D., Sindelar D.K. The direct and indirect effects of insulin on hepatic glucose production in vivo. Diabetologia. 1998;41:987–996.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9754815</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Edgerton D.S., Kraft G., Smith M., Farmer B., Williams P.E., Coate K.C., Printz R.L., O'Brien R.M., Cherrington A.D. Insulin’s direct hepatic effect explains the inhibition of glucose production caused by insulin secretion. JCI Insight. 2017;2:e91863.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5358484</ArticleId>
            <ArticleId IdType="pubmed">28352665</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cherrington A.D., Moore M.C., Sindelar D.K., Edgerton D.S. Insulin action on the liver in vivo. Biochem Soc Trans. 2007;35:1171–1174.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17956305</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Altomonte J., Richter A., Harbaran S., Suriawinata J., Nakae J., Thung S.N., Meseck M., Accili D., Dong H. Inhibition of Foxo1 function is associated with improved fasting glycemia in diabetic mice. Am J Physiol Endocrinol Metab. 2003;285:E718–E728.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12783775</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Matsumoto M., Pocai A., Rossetti L., DePinho R.A., Accili D. Impaired regulation of hepatic glucose production in mice lacking the forkhead transcription factor Foxo1 in liver. Cell Metab. 2007;6:208–216.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17767907</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Titchenell P.M., Lazar M.A., Birnbaum M.J. Unraveling the regulation of hepatic metabolism by insulin. Trends Endocrinol Metab. 2017;28:497–505.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5477655</ArticleId>
            <ArticleId IdType="pubmed">28416361</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Myers M.G., Olson D.P. Central nervous system control of metabolism. Nature. 2012;491:357–363.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23151578</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Belgardt B.F., Okamura T., Brüning J.C. Hormone and glucose signalling in POMC and AgRP neurons. J Physiol. 2009;587:5305–5314.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2793863</ArticleId>
            <ArticleId IdType="pubmed">19770186</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Könner A.C., Janoschek R., Plum L., Jordan S.D., Rother E., Ma X., Xu C., Enriori P., Hampel B., Barsh G.S., Kahn C.R., Cowley M.A., Ashcroft F.M., Brüning J.C. Insulin action in AgRP-expressing neurons is required for suppression of hepatic glucose production. Cell Metab. 2007;5:438–449.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17550779</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pocai A., Lam T.K.T., Gutierrez-Juarez R., Obici S., Schwartz G.J., Bryan J., Aguilar-Bryan L., Rossetti L. Hypothalamic KATP channels control hepatic glucose production. Nature. 2005;434:1026–1031.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15846348</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Inoue H., Ogawa W., Asakawa A., Okamoto Y., Nishizawa A., Matsumoto M., Teshigawara K., Matsuki Y., Watanabe E., Hiramatsu R., Notohara K., Katayose K., Okamura H., Kahn C.R., Noda T., Takeda K., Akira S., Inui A., Kasuga M. Role of hepatic STAT3 in brain-insulin action on hepatic glucose production. Cell Metab. 2006;3:267–275.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16581004</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Obici S., Zhang B.B., Karkanias G., Rossetti L. Hypothalamic insulin signaling is required for inhibition of glucose production. Nat Med. 2002;8:1376–1382.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12426561</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lam T.K.T., Pocai A., Gutierrez-Juarez R., Obici S., Bryan J., Aguilar-Bryan L., Schwartz G.J., Rossetti L. Hypothalamic sensing of circulating fatty acids is required for glucose homeostasis. Nat Med. 2005;11:320–327.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15735652</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Altarejos J.Y., Montminy M. CREB and the CRTC co-activators: sensors for hormonal and metabolic signals. Nat Rev Mol Cell Biol. 2011;12:141–151.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4324555</ArticleId>
            <ArticleId IdType="pubmed">21346730</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>O’Brien R.M., Granner D.K. Regulation of gene expression by insulin. Physiol Rev. 1996;76:1109–1161.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8874496</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cherrington A.D. Control of glucose uptake and release by the liver in vivo. Diabetes. 1999;48:1198–1214.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10331429</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Myers S.R., Diamond M.P., Adkins-Marshall B.A., Williams P.E., Stinsen R., Cherrington A.D. Effects of small changes in glucagon on glucose production during a euglycemic, hyperinsulinemic clamp. Metabolism. 1991;40:66–71.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">1984573</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sharma A., Varghese R.T., Shah M., Man C.D., Cobelli C., Rizza R.A., Bailey K.R., Vella A. Impaired insulin action is associated with increased glucagon concentrations in nondiabetic humans. J Clin Endocrinol Metab. 2018;103:314–319.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5761487</ArticleId>
            <ArticleId IdType="pubmed">29126197</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kawamori D., Kurpad A.J., Hu J., Liew C.W., Shih J.L., Eric L., Herrera P.L., Polonsky K.S., McGuinness O.P., Kulkarni R.N. Insulin signaling in alpha cells modulates glucagon secretion in vivo. Cell Metab. 2009;9:350–361.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2694613</ArticleId>
            <ArticleId IdType="pubmed">19356716</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lefèbvre P.J., Paquot N., Scheen A.J. Inhibiting or antagonizing glucagon: making progress in diabetes care. Diabetes Obes Metab. 2015;17:720–725.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25924114</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mittelman S.D., Fu Y.Y., Rebrin K., Steil G.M., Bergman R.N. Indirect effect of insulin to suppress endogeneous glucose production is dominant, even with hyperglucoagonemia. J Clin Invest. 1997;100:3121–3130.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC508525</ArticleId>
            <ArticleId IdType="pubmed">9399959</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rebrin K., Steil G.M., Getty L., Bergman R.N. Free fatty acid as a link in the regulation of hepatic glucose output by peripheral insulin. Diabetes. 1995;44:1038–1045.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">7657026</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sindelar D.K., Chu C.A., Rohlie M., Neal D.W., Swift L.L., Cherrington A.D. The role of fatty acids in mediating the effects of peripheral insulin on hepatic glucose production in the conscious dog. Diabetes. 1997;46:187–196.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9000693</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chu C.A., Sherck S.M., Igawa K., Sindelar D.K., Neal D.W., Emshwiller M., Cherrington A.D. Effects of free fatty acids on hepatic glycogenolysis and gluconeogenesis in conscious dogs. Am J Physiol Endocrinol Metab. 2002;282:E402–E411.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11788373</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Perry R.J., Camporez J.G., Kursawe R., Titchenell P.M., Zhang D., Perry C.J., Jurczak M.J., Abudukadier A., Han S., Zhang X.M., Ruan H.B., Yang X., Caprio S., Susan M., Sul H.S., Birnbaum M.J., Davis R.J., Cline G.W., Falk K., Shulman G.I. Hepatic acetyl CoA links adipose tissue inflammation to hepatic insulin resistance and type 2 diabetes. 2015;160:745–758.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4498261</ArticleId>
            <ArticleId IdType="pubmed">25662011</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen C., Williams P.F., Cooney G.J., Caterson I.D., Turtle J.R. The effects of fasting and refeeding on liver glycogen synthase and phosphorylase in obese and lean mice. Horm Metab Res. 1992;24:161–166.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">1601390</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim J.K., Kim Y.J., Fillmore J.J., Chen Y., Moore I., Lee J., Yuan M., Li Z.W., Karin M., Perret P., Shoelson S.E., Shulman G.I. Prevention of fat-induced insulin resistance by salicylate. J Clin Invest. 2001;108:437–446.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC209353</ArticleId>
            <ArticleId IdType="pubmed">11489937</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Edgerton D.S., Lautz M., Scott M., Everett C.A., Stettler K.M., Neal D.W., Chu C.A., Cherrington A.D. Insulin’ s direct effects on the liver dominate the control of hepatic glucose production. J Clin Invest. 2006;116:521–527.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1359060</ArticleId>
            <ArticleId IdType="pubmed">16453026</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
